ChromaDex Corporation

CDXC

US1710774076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 23/05/2024 am IST			5-day change	1st Jan Change
3.17 ^USD	+0.32%		-12.67%	+121.68%

08/05	Transcript : ChromaDex Corporation, Q1 2024 Earnings Call, May 08, 2024
08/05	Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q1 Revenue $22.2M, vs. Street Est of $23.6M	MT

ChromaDex Corporation Announces Resignation of Tony Lau from the Board of Directors and Member of the Compensation Committee of the Board

October 30, 2021 at 02:59 am IST

On October 19, 2021, Tony Lau notified ChromaDex Corporation of his intention to resign from the board of directors of the Company and as a member of the Compensation Committee of the Board.

Latest news about ChromaDex Corporation

Transcript : ChromaDex Corporation, Q1 2024 Earnings Call, May 08, 2024	09/05
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q1 Revenue $22.2M, vs. Street Est of $23.6M	09/05	MT
ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024	09/05	CI
ChromaDex Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Chromadex Corp. Announces an Ingredient Partnership with Solgar	30/04	CI
Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market	23/04	CI
Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	09/04	MT
HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating	11/03	MT
Transcript : ChromaDex Corporation, Q4 2023 Earnings Call, Mar 06, 2024	07/03
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $21.2M, vs. Street Est of $20.7M	07/03	MT
ChromaDex Corporation Provides Earnings Guidance for 2024	07/03	CI
ChromaDex Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
ChromaDex Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
ChromaDex Corporation, Chromadex, Inc. and ChromaDex Analytics, Inc Enter into an Amendment to the Business Financing Agreement Dated November 1, 2019 Among the Borrowers and Western Alliance Bank	14/12	CI
Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+	12/12	CI
ChromaDex Says High-Dose Niagen Safe for Parkinson's Disease Patients in Phase 1 Study	30/11	MT
Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)	30/11	CI
ChromaDex Reports Positive Data From Phase 2 Study Using Niagen	15/11	MT
Chromadex Corp. Shares Results from Phase II Clinical Study	15/11	CI
Transcript : ChromaDex Corporation, Q3 2023 Earnings Call, Nov 08, 2023	09/11
Earnings Flash (CDXC) CHROMADEX CORPORATION Posts Q3 Revenue $19.5M, vs. Street Est of $20.4M	09/11	MT
ChromaDex Corporation Provides Revenue Guidance for the Year 2023	09/11	CI
ChromaDex Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
ChromaDex Launches New Food Supplement	01/11	MT
ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)	01/11	CI

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Sector

Biotechnology & Medical Research

Calendar

30/05/2024 - Lytham Partners Spring Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for ChromaDex Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.17 USD

Average target price

6.34 USD

Spread / Average Target

+100.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHROMADEX CORPORATION	+121.68%	24Cr
MODERNA, INC.	+64.23%	5.51TCr
IQVIA HOLDINGS INC.	-2.31%	4.18TCr
LONZA GROUP AG	+44.36%	4.02TCr
CELLTRION, INC.	-8.29%	2.82TCr
ICON PUBLIC LIMITED COMPANY	+11.97%	2.63TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	1.89TCr
BIO-TECHNE CORPORATION	+7.54%	1.3TCr
MEDPACE HOLDINGS, INC.	+27.17%	1.23TCr
UNITED THERAPEUTICS CORPORATION	+25.72%	1.22TCr

Other Biotechnology & Medical Research